Silence Therapeutics (SLN) Research & Development (2020 - 2026)
Silence Therapeutics recorded quarterly Research & Development of $9.1 million in Q1 2026, down 67.07% quarter-over-quarter from $27.7 million in Q4 2025, and down 56.17% year-over-year from $20.8 million in Q1 2025.
Silence Therapeutics' Research & Development history runs 7 years deep, the most recent figure standing at $9.1 million for Q1 2026.
- In Q1 2026, Research & Development fell 56.17% year-over-year to $9.1 million; the TTM figure through Mar 2026 stood at $75.0 million (up 63.65% YoY), while the FY2025 annual figure was $67.8 million, up 57.93% from the prior year.
- Research & Development came in at $9.1 million for Q1 2026 at Silence Therapeutics, down from $27.7 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $97.0 million in Q4 2023 to a low of -$15.8 million in Q2 2023.
- A 5-year average of $13.0 million and a median of $7.8 million in 2024 frame the typical range for Research & Development.
- Across the five-year window, Research & Development tumbled 103.0% in 2024 and jumped 1053.89% in 2025, its largest moves.
- Silence Therapeutics' Research & Development stood at $73.7 million in 2022, then soared by 31.6% to $97.0 million in 2023, then sank by 103.0% to -$2.9 million in 2024, then surged by 1053.89% to $27.7 million in 2025, then slumped by 67.07% to $9.1 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $9.1 million, $27.7 million, and $20.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -2.30 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.54 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 364.87 Mn |
| 10 | Silence Therapeutics | 924.61 Mn | 854.53 Mn | 411,000.00 | 9.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.12 Mn |
| Dec 31, 2025 | 27.70 Mn |
| Sep 30, 2025 | 20.54 Mn |
| Jun 30, 2025 | 17.65 Mn |
| Mar 31, 2025 | 20.81 Mn |
| Dec 31, 2024 | -2.90 Mn |
| Sep 30, 2024 | 20.16 Mn |
| Jun 30, 2024 | 7.77 Mn |
| Mar 31, 2024 | 6.30 Mn |
| Dec 31, 2023 | 96.95 Mn |
| Sep 30, 2023 | -11.32 Mn |
| Jun 30, 2023 | -15.79 Mn |
| Mar 31, 2023 | -15.24 Mn |
| Dec 31, 2022 | 73.67 Mn |
| Sep 30, 2022 | -10.34 Mn |
| Jun 30, 2022 | -13.64 Mn |
| Mar 31, 2022 | -10.20 Mn |
| Dec 31, 2021 | 73.21 Mn |
| Sep 30, 2021 | -10.91 Mn |
| Jun 30, 2021 | -11.42 Mn |
| Mar 31, 2021 | -10.28 Bn |
| Dec 31, 2020 | 18.05 Bn |
| Sep 30, 2020 | -4.48 Bn |